399 BINNEY STREET, CAMBRIDGE, MA
Relay Therapeutics Increases Authorized Shares to 450 Million
Relay Therapeutics Enters Underwriting Agreement for $296.8 Million Offering
Investor Presentation
Reports First Quarter 2026 Financial Results and Corporate Updates
Annual Report to Security Holders
Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics Amends Bylaws to Designate Exclusive Forum
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)